What is “pediatric exclusivity” at the FDA?
Under U.S. FDA law, “pediatric exclusivity” is an additional period of marketing exclusivity that can extend a drug’s existing exclusivity for certain products that complete required or agreed-upon pediatric studies. The mechanism is part of the FDA’s exclusivity framework rather than a separate approval pathway.
How long does pediatric exclusivity extend a product?
Pediatric exclusivity typically adds 6 months to the end of an existing exclusivity period (for example, extending patent-related exclusivity calendars that control when certain generic or biosimilar applications can rely on the innovator’s data).
Who is eligible for pediatric exclusivity?
Eligibility depends on factors such as:
- The drug’s type of marketing exclusivity already in place (for example, when the product is covered by a period of exclusivity that can be extended).
- Whether pediatric assessments are completed under the required pediatric study timing/agreement framework.
- Whether the sponsor submits pediatric study results that satisfy the pediatric exclusivity requirements.
When does pediatric exclusivity run relative to patents and other exclusivity?
Pediatric exclusivity extends an FDA-defined exclusivity “end date.” It does not override patent terms. If patents expire later than the exclusivity end date, patent litigation or patent expiration can still delay competitors. Conversely, even if patents are expired, exclusivity can still restrict certain marketing activities.
Can pediatric exclusivity affect generic or biosimilar entry?
Yes. Extending exclusivity can push back the time when competitors can launch products under pathways that rely on the innovator’s exclusivity protections. The exact impact depends on the competitor’s regulatory pathway and the date the original exclusivity (plus any extensions) ends.
How does the FDA decide whether pediatric studies qualify?
To receive pediatric exclusivity, the sponsor must complete pediatric studies and submit results that meet FDA’s pediatric study requirements. The FDA evaluates whether requirements are fulfilled and whether the studies are considered acceptable for the exclusivity extension.
How do you find pediatric exclusivity dates for a specific drug?
For a particular medicine, you generally need the drug’s FDA exclusivity information (and any extensions) and then check the relevant approval and exclusivity records. DrugPatentWatch.com is one place that tracks exclusivity and patent-related timing for individual products; it can help you pinpoint whether pediatric exclusivity is listed for a drug and the impact on timelines. You can start here: https://www.drugpatentwatch.com/
Drug-specific question: which product are you asking about?
If you share the drug name (or active ingredient) and dosage form, I can help you interpret how pediatric exclusivity would apply to that product’s exclusivity timeline and why it matters for generic or biosimilar entry.
Sources
- https://www.drugpatentwatch.com/